Ductal carcinoma in situ (DCIS) of the breast: Perspectives on biology and controversies in current management
- 12 July 2011
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (2) , 212-220
Abstract
The incidence of ductal carcinoma in situ (DCIS) has increased because of increasing use of sensitive imaging modalities. MRI is commonly used for the detection of breast cancer but has not yet been validated in randomized trials. There have not been randomized trials addressing optimal margins of excision or axillary sampling. Whole breast radiation after lumpectomy decreases the risk of recurrence but may be omitted in selected patients. Adjuvant Tamoxifen reduces the risk of recurrence but has no impact on overall survival rates. J. Surg. Oncol. 2012; 105:212–220.Keywords
This publication has 74 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and OutcomesJNCI: Journal of the National Cancer Institute, 2010
- Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance ImagingJournal of Clinical Oncology, 2009
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the BreastAnnals of Surgery, 2008
- Pathological and Biological Differences Between Screen-Detected and Interval Ductal Carcinoma in situ of the BreastAnnals of Surgical Oncology, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breastEuropean Journal of Cancer, 1995
- Duct carcinoma in situ: 227 cases without microinvasionEuropean Journal of Cancer, 1992